# 60 Degrees Pharmaceuticals, Inc.: Form 10-Q for the period ended Sep 30, 2023

- Company: [60 Degrees Pharmaceuticals, Inc.](/companies/sxtp.md) (CIK 1946563)
- Form: 10-Q
- Filed: 2023-11-20
- Accepted by EDGAR: Nov 20, 2023, 12:41 ET
- Period: 2023-09-30
- Accession: 0001213900-23-088610
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1946563/000121390023088610/f10q0923_60degrees.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1946563/000121390023088610/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-07-01 to 2023-09-30 | $51.2k | us-gaap:Revenues |
| Revenue | 9 months, 2023-01-01 to 2023-09-30 | $127.9k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2023-07-01 to 2023-09-30 | $71.2k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2023-01-01 to 2023-09-30 | $328.3k | us-gaap:CostOfRevenue |
| Research and development | 3 months, 2023-07-01 to 2023-09-30 | $263.7k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2023-01-01 to 2023-09-30 | $591.6k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2023-07-01 to 2023-09-30 | −$1.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2023-01-01 to 2023-09-30 | −$3.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-07-01 to 2023-09-30 | $40.1k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2023-01-01 to 2023-09-30 | $2.3m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-07-01 to 2023-09-30 | $63 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2023-01-01 to 2023-09-30 | $189 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-07-01 to 2023-09-30 | $4.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2023-01-01 to 2023-09-30 | −$1.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-07-01 to 2023-09-30 | $0.77 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2023-01-01 to 2023-09-30 | −$0.55 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-07-01 to 2023-09-30 | $0.77 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2023-01-01 to 2023-09-30 | −$0.55 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-07-01 to 2023-09-30 | 5,319,255 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2023-01-01 to 2023-09-30 | 3,344,843 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2023-01-01 to 2023-09-30 | −$4.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2023-01-01 to 2023-09-30 | $1.8k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-09-30 | $2.2m | us-gaap:Cash |
| Current assets | at 2023-09-30 | $8.9m | us-gaap:AssetsCurrent |
| Total assets | at 2023-09-30 | $9.2m | us-gaap:Assets |
| Current liabilities | at 2023-09-30 | $2.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-09-30 | $2.6m | us-gaap:Liabilities |
| Long-term debt | at 2023-09-30 | $150.0k | us-gaap:LongTermDebt |
| Shareholders' equity | at 2023-09-30 | $6.5m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Sections

EDGAR did not return this filing’s main document when we asked, so its sections were not extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1946563/000121390023088610/f10q0923_60degrees.htm

Filed Nov 20, 2023.
Source: SEC EDGAR, the filing index for accession 0001213900-23-088610. Last ingested by Listed: Nov 6, 2026, 12:18 ET. No prices; not investment advice.